收稿日期: 2024-02-21
网络出版日期: 2024-08-26
基金资助
国家自然科学基金项目(82172215);广东省基础与应用基础研究基金项目(2021A1515012109);深圳市科技创新委员基础研究专项面上项目(JCYJ202308 07111302006);深圳市福田区卫生健康系统科研项目(FTWS2023056)
Serological biomarkers for diagnosis of diabetes foot： A review of literature
Received date: 2024-02-21
Online published: 2024-08-26
糖尿病足（diabetic foot， DF）是糖尿病的一种主要慢性并发症，也是糖尿病患者致残和致死的主要原因。目前，DF的诊断主要依赖临床表现、体征及相关辅助检查，生物学标志物的发现及应用对DF的临床诊疗提供重要帮助。随着生物学的发展，除广泛应用的降钙素原（procalcitonin， PCT）、C反应蛋白（C-reactive protein， CRP）、白细胞介素（interleukins， ILs）和肿瘤坏死因子-α（tumor necrosis factor-alpha， TNF-α）等炎性标志物指标外，基因组学、蛋白质组学、代谢组学和微生物组学已经用于诊断DF。为了进一步了解血清生物学标志物在DF诊断中的应用和研究现状，本综述将详细讨论和总结DF诊断标志物，为预防、诊断和预后评估提供相应依据。
杨卡明 , 李贞林 , 劳琬文 , 翟爱霞 , 毕长龙 . 糖尿病足血清学诊断标志物的研究进展[J]. 实用医学杂志, 2024 , 40(16) : 2224 -2228 . DOI: 10.3969/j.issn.1006-5725.2024.16.005
Diabetic foot （DF）， a primary chronic complication of diabetes mellitus， contributes to a major disability and mortality in diabetic patients. DF is diagnosed mainly depending not only on clinical manifestations， signs， and related inspection， but also on recently emerging diagnostic means： biological markers. Inflammatory biomarkers are preferably used for its superiority in DF early diagnosis. In recently years， thanks to advancements of biological technologies， biomarkers such as procalcitonin （PCT）， C?reactive protein （CRP）， interleukins （ILs）， and tumor necrosis factor?alpha （TNF?α） have been comprehensively used in DF diagnosis. Moreover， biomarkers of genomics， proteomics， metabolomics， and metagenomics have been employed as well. In this review， we aim to comprehensively review the role of serum biomarkers in DF diagnosis and risk stratification， elaborating on the current research status in applying serum biomarkers for DF prevention， diagnosis， and prognosis assessment.
Key words： diabetic foot; diagnostic marker; serological biomarkers
| 1 | Diabetes Atlas IDF. 2022 ［DB/OL］ （. |
| 2 | GAZZARUSO C， GALLOTTI P， PUJIA A， et al. Predictors of healing， ulcer recurrence and persistence， amputation and mortality in type 2 diabetic patients with diabetic foot： a 10-year retrospective cohort study ［J］. Endocrine，2021，71（1）：59-68. doi:10.1007/s12020-020-02431-0 |
| 3 | MONTEIRO-SOARES M， SCHAPER N C. Definitions and criteria for diabetic foot disease ［J］. Diabetes Metab Res Rev， 2020，36 （）：e3268. doi:10.1002/dmrr.3268 |
| 4 | DEN DEKKER A， DAVIS F M， KUNKEL S L， et al. Targeting epigenetic mechanisms in diabetic wound healing ［J］. Transl Res，2019，204：39-50. doi:10.1016/j.trsl.2018.10.001 |
| 5 | LI B， LUAN S， CHEN J， et al. The MSC-Derived Exosomal lncRNA H19 Promotes Wound Healing in Diabetic Foot Ulcers by Upregulating PTEN via MicroRNA-152-3p ［J］. Mol Ther Nucleic Acids， 2020，19：814-826. doi:10.1016/j.omtn.2019.11.034 |
| 6 | UMAPATHY D， DORNADULA S， RAJAGOPALAN A， et al. Potential of circulatory procalcitonin as a biomarker reflecting inflammation among South Indian diabetic foot ulcers ［J］. J Vasc Surg， 2018，67（4）：1283-1291.e2. doi:10.1016/j.jvs.2017.02.060 |
| 7 | MELONI M， IZZO V， GIURATO L， et al. Procalcitonin Is a Prognostic Marker of Hospital Outcomes in Patients with Critical Limb Ischemia and Diabetic Foot Infection ［J］. J Diabetes Res， 2019，2019：4312737. doi:10.1155/2019/4312737 |
| 8 | TODOROVA A S， DIMOVA R B， CHAKAROVA N Y， et al. Comparative Evaluation of the Diagnostic Value of Procalcitonin and hsCRP for the Presence of Mild-to-Moderate Diabetic Foot Infections ［J］. Int J Low Extrem Wounds， 2023，22（2）：353-359. doi:10.1177/15347346211011849 |
| 9 | INGRAM J R， CAWLEY S， COULMAN E， et al. Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy （INDUCE study） ［J］. Diabet Med， 2018，35（2）：255-261. doi:10.1111/dme.13431 |
| 10 | MCFADYEN J D， KIEFER J， BRAIG D， et al. Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation： Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes ［J］. Front Immunol， 2018，9：1351. doi:10.3389/fimmu.2018.01351 |
| 11 | METINEREN H， DüLGERO?LU T C. Comparison of the Neutrophil/Lymphocyte Ratio and C-Reactive Protein Levels in Patients With Amputation for Diabetic Foot Ulcers ［J］. Int J Low Extrem Wounds， 2017，16（1）：23-28. doi:10.1177/1534734617696729 |
| 12 | LAVERY L A， AHN J， RYAN E C， et al. Erratum to： What are the Optimal Cutoff Values for ESR and CRP to Diagnose Osteomyelitis in Patients with Diabetes-related Foot Infections？ ［J］. Clin Orthop Relat Res， 2020，478（4）：923. doi:10.1097/corr.0000000000001192 |
| 13 | ZUBAIR M， AHMAD J. Role of growth factors and cytokines in diabetic foot ulcer healing： A detailed review ［J］. Rev Endocr Metab Disord， 2019，20（2）：207-217. doi:10.1007/s11154-019-09492-1 |
| 14 | CHEN Z， QIN X， ZHANG X， et al. Upregulation of IL-4 signaling contributes to aerobic exercise-induced insulin sensitivity ［J］. Biochem Biophys Res Commun， 2020，525（3）：662-667. doi:10.1016/j.bbrc.2020.02.103 |
| 15 | HAMMAD R， ELMADBOULY A A， AHMAD I H， et al. T-Natural Killers and Interferon Gamma/Interleukin 4 in Augmentation of Infection in Foot Ulcer in Type 2 Diabetes ［J］. Diabetes Metab Syndr Obes， 2021，14：1897-1908. doi:10.2147/dmso.s305511 |
| 16 | VISWANATHAN V， DHAMODHARAN U， SRINIVASAN V， et al. Single nucleotide polymorphisms in cytokine/chemokine genes are associated with severe infection， ulcer grade and amputation in diabetic foot ulcer ［J］. Int J Biol Macromol， 2018，118（Pt B）：1995-2000. doi:10.1016/j.ijbiomac.2018.07.083 |
| 17 | CRISOLOGO P A， DAVIS K E， AHN J， et al. The infected diabetic foot： Can serum biomarkers predict osteomyelitis after hospital discharge for diabetic foot infections？ ［J］. Wound Repair Regen， 2020，28（5）：617-622. doi:10.1111/wrr.12836 |
| 18 | RAI V， MOELLMER R， AGRAWAL D K. The role of CXCL8 in chronic nonhealing diabetic foot ulcers and phenotypic changes in fibroblasts： a molecular perspective ［J］. Mol Biol Rep， 2022，49（2）：1565-1572. doi:10.1007/s11033-022-07144-3 |
| 19 | ZHANG F， LIU Y， WANG S， et al. Interleukin-25-Mediated-IL-17RB Upregulation Promotes Cutaneous Wound Healing in Diabetic Mice by Improving Endothelial Cell Functions ［J］. Front Immunol， 2022，13：809755. doi:10.3389/fimmu.2022.809755 |
| 20 | KOLUMAM G， WU X， LEE W P， et al. IL-22R Ligands IL-20， IL-22， and IL-24 Promote Wound Healing in Diabetic db/db Mice ［J］. PLoS One， 2017，12（1）：e0170639. doi:10.1371/journal.pone.0170639 |
| 21 | Angiogenesis in Health， Diseases and Malignancy ［J］. Anticancer Res， 2016， 36： 3226. doi:10.1007/978-3-319-28140-7_6 |
| 22 | DHAMODHARAN U， TEENA R， VIMAL KUMAR R， et al. Circulatory levels of B-cell activating factor of the TNF family in patients with diabetic foot ulcer： Association with disease progression ［J］. Wound Repair Regen， 2019，27（5）：442-449. doi:10.1111/wrr.12720 |
| 23 | OZER BALIN S， SAGMAK TARTAR A， U?UR K， et al. Pentraxin-3： A new parameter in predicting the severity of diabetic foot infection？ ［J］. Int Wound J， 2019，16（3）：659-664. doi:10.1111/iwj.13075 |
| 24 | TAKASHI Y， KOGA M， MATSUZAWA Y， et al. Circulating pentraxin 3 is positively associated with chronic hyperglycemia but negatively associated with plasma aldosterone concentration ［J］. PLoS One， 2018，13（5）：e0196526. doi:10.1371/journal.pone.0196526 |
| 25 | RASMUSSEN L J H， PETERSEN J E V， EUGEN-OLSEN J. Soluble Urokinase Plasminogen Activator Receptor （suPAR） as a Biomarker of Systemic Chronic Inflammation ［J］. Front Immunol，2021，12：780641. doi:10.3389/fimmu.2021.780641 |
| 26 | ASLAN S， DEMIRDAL T， ERBAK H， et al. The role of soluble urokinase plasminogen activator receptor （suPAR） in the diagnostics of diabetic foot infection ［J］. Infect Dis （Lond）， 2020，52（2）：107-113. doi:10.1080/23744235.2019.1688387 |
| 27 | ZUBAIR M， AHMAD J. Heat Shock Protein 70 Gene Single Nucleotide Polymorphism and Diabetic Foot Ulcer. Is There Any Relationship？ ［J］. J Clin Med， 2018，7（8）：187. doi:10.3390/jcm7080187 |
| 28 | LI X， LU Y， WEI P. Association between VEGF genetic variants and diabetic foot ulcer in Chinese Han population： A case-control study ［J］. Medicine （Baltimore）， 2018， 97（20）：e10672. doi:10.1097/md.0000000000010672 |
| 29 | PICHU S， SATHIYAMOORTHY J， VIMALRAJ S， et al. Impact of lysyl oxidase （G473A） polymorphism on diabetic foot ulcers ［J］. Int J Biol Macromol， 2017，103：242-247. doi:10.1016/j.ijbiomac.2017.05.050 |
| 30 | LIN C J， LAN YM， OU M Q， et al. Expression of miR-217 and HIF-1α/VEGF pathway in patients with diabetic foot ulcer and its effect on angiogenesis of diabetic foot ulcer rats ［J］. J Endocrinol Invest， 2019，42（11）：1307-1317. doi:10.1007/s40618-019-01053-2 |
| 31 | AMIN K N， UMAPATHY D， ANANDHARAJ A， et al. miR-23c regulates wound healing by targeting stromal cell-derived factor-1α （SDF-1α/CXCL12） among patients with diabetic foot ulcer ［J］. Microvasc Res， 2020，127：103924. doi:10.1016/j.mvr.2019.103924 |
| 32 | GAO J， ZHAO G， LI W， et al. MiR-155 targets PTCH1 to mediate endothelial progenitor cell dysfunction caused by high glucose ［J］. Exp Cell Res， 2018，366（1）：55-62. doi:10.1016/j.yexcr.2018.03.012 |
| 33 | JONES J I， NGUYEN T T， PENG Z， et al. Targeting MMP-9 in Diabetic Foot Ulcers ［J］. Pharmaceuticals （Basel）， 2019，12（2）：79. doi:10.3390/ph12020079 |
| 34 | HUNG S Y， TSAI J S， YEH J T， et al. Amino acids and wound healing in people with limb-threatening diabetic foot ulcers ［J］. J Diabetes Complications， 2019，33（10）：107403. doi:10.1016/j.jdiacomp.2019.06.008 |
| 35 | SADEGHPOUR HERAVI F， ZAKRZEWSKI M， VICKERY K， et al. Bacterial Diversity of Diabetic Foot Ulcers： Current Status and Future Prospectives ［J］. J Clin Med， 2019，8（11）：1935. doi:10.3390/jcm8111935 |
| 36 | COLLIER A， MCLAREN J， GODWIN J， et al. Is Clostridium difficile associated with the '4C' antibiotics？ A retrospective observational study in diabetic foot ulcer patients ［J］. Int J Clin Pract， 2014，68（5）：628-632. doi:10.1111/ijcp.12347 |
| 37 | 李婉媚，杨旭斌，黄懿文，等. 血糖波动对糖尿病大鼠心脏自主神经功能的影响及其机制［J］. 实用医学杂志， 2021，37（16）：2065-2068+2074. doi:10.3969/j.issn.1006-5725.2021.16.006 |
/
| 〈 |
|
〉 |